Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Academic Article uri icon

Overview

abstract

  • OBJECTIVE: To determine why methotrexate (MTX) exacerbates rheumatoid nodules in some patients, despite the effective suppression of synovial inflammation. METHODS: Phorbol myristate acetate (PMA)-induced differentiation of monocytes into multinucleated giant cells was used as an in vitro model to study the effects of adenosine on nodulosis. RESULTS: MTX at 200-2,000 nM or the adenosine A1 agonist N5-cyclopentyl adenosine (CPA) (10(-12) to 10(-9) M) or the A2 antagonist 3,7-dimethyl-1-propargylxanthine markedly enhanced giant cell formation, whereas the adenosine A1 antagonist 8-cyclopentyl-dipropylxanthine completely reversed these effects. PMA, CPA, and MTX induced adenosine release by cultured monocytes at concentrations consistent with those associated with predominantly A1 effects. Furthermore, surface expression of A1 receptors was found to remain unchanged on the differentiating cells throughout the culture period. CONCLUSION: Agents that inhibit adenosine A1 receptors might be useful in the treatment of MTX-induced rheumatoid nodulosis, while still potentiating the A2-mediated antiinflammatory effects of MTX on synovitis.

publication date

  • July 1, 1997

Research

keywords

  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Methotrexate
  • Monocytes
  • Receptors, Purinergic P1
  • Rheumatoid Nodule

Identity

Scopus Document Identifier

  • 0030612493

Digital Object Identifier (DOI)

  • 10.1002/1529-0131(199707)40:7<1308::AID-ART16>3.0.CO;2-M

PubMed ID

  • 9214432

Additional Document Info

volume

  • 40

issue

  • 7